US20100227806A1 - Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment - Google Patents

Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment Download PDF

Info

Publication number
US20100227806A1
US20100227806A1 US12/224,972 US22497207A US2010227806A1 US 20100227806 A1 US20100227806 A1 US 20100227806A1 US 22497207 A US22497207 A US 22497207A US 2010227806 A1 US2010227806 A1 US 2010227806A1
Authority
US
United States
Prior art keywords
administration
individual
reduction
glucocorticoids
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/224,972
Other languages
English (en)
Inventor
Tulipano Giovanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to US12/224,972 priority Critical patent/US20100227806A1/en
Assigned to SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. reassignment SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GIUSTINA, ANDREA, TULIPANO, GIOVANNI
Assigned to BIOMEASURE, INCORPORATED reassignment BIOMEASURE, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CULLER, MICHAEL DEWITT, DONG, ZHENG XIN
Assigned to SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. reassignment SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOMEASURE INCORPORATED
Publication of US20100227806A1 publication Critical patent/US20100227806A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Definitions

  • Glucocorticoids are a class of steroid hormones characterized by an ability to bind with the cortisol receptor and trigger similar effects. Glucocorticoids have potent anti-inflammatory and immunosuppressive properties and as such are the best-known class of anti-inflammatory active ingredients. Owing to their broad range of uses and their great anti-inflammatory action, corticoid preparations are therapeutic agents of first choice in a wide variety of inflammatory diseases, such as, for example, diseases of the rheumatoid group, allergies, inflammatory diseases of the lungs, heart, and intestines, bronchial asthma, hyperproliferative diseases of the skin (psoriasis), eczemas, auto-immune diseases, or states of shock.
  • inflammatory diseases such as, for example, diseases of the rheumatoid group, allergies, inflammatory diseases of the lungs, heart, and intestines, bronchial asthma, hyperproliferative diseases of the skin (psoriasis), e
  • Dexamethasone a synthetic member of the glucocorticoid class of hormones which exhibits anti-inflammatory and immunosuppressive properties which are 40 times more potent than naturally-occurring hydrocortisone and having the following structure,
  • 9-fluoro-11 ⁇ ,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione has been shown to augment the antiemetic effect of 5-HT 3 receptor antagonists.
  • Dexamethasone is used to treat many inflammatory and autoimmune conditions, such as rheumatoid arthritis. It is also given to cancer patients undergoing chemotherapy to counteract certain side-effects.
  • Glucocorticoids particularly dexamethasone
  • dexamethasone have been used for years to treat preterm infants who have or are at risk for chronic lung disease (The, T. F. et al., Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease in Preterm Infants with Respiratory Distress Syndrome: A Multicenter Clinical Trial, 1997, 100:715-6). These agents often have the short-term benefits of improving lung compliance and facilitating early weaning from mechanical ventilation. Newborns, with extremely low birth weight (ELBW), traditionally receive early postnatal dexamethasone therapy to treat and/or prevent severe respiratory distress syndrome and the subsequent onset of chronic lung disease.
  • ELBW extremely low birth weight
  • Human growth hormone also may be referred to herein as “GH”
  • GH Human growth hormone
  • 191 amino acids molecular weight 21,500
  • Disulfide bonds link positions 53 and 165 and positions 182 and 189 (Niall, Nature, New Biology , (1971), 230: 90). Effects of growth hormone on the tissues of the body can generally be described as anabolic (building up).
  • GH acts by interacting with a specific receptor on the surface of cells. Height growth in childhood is the best known effect of GH action.
  • GH also stimulates production of insulin-like growth factor 1 (may also be referred to herein as “IGF-1”) which demonstrates growth-stimulating effects on a wide variety of tissues.
  • IGF-1 insulin-like growth factor 1
  • GH also serves many other metabolic functions such as increasing calcium retention and mineralization in bones, increasing muscle mass by inducing protein synthesis, stimulating the immune system, reducing liver uptake of glucose thus contributing to the maintenance and function of pancreatic islets and promoting lipolysis, which results in some reduction of adipose tissue (body fat) and rising amounts of free fatty acids and glycerol in the blood.
  • the pulsatile release of growth hormone from the pituitary somatotrops is regulated by two hypothalamic neuropeptides: growth hormone-releasing hormone and somatostatin.
  • Growth hormone-releasing hormone stimulates release of growth hormone whereas somatostatin inhibits secretion of growth hormone (Frohman et al., Endocrinology Review (1986) 7:223-53 and Strobi et al., Pharmacology Review (1994) 46:1-34).
  • Most GH deficiencies are caused by defects in GH release, not primary defects in pituitary synthesis of the hormone itself.
  • Increasing GH secretion can be achieved by stimulating or inhibiting various neurotransmitter systems in the brain and hypothalamus.
  • glucocorticoid mediated growth inhibition is most likely multifactorial in nature involving, partial growth hormone resistance, suppression of IGF-1 activity, and antagonism of insulin activity. These factors all influence carbohydrate and lipid metabolism.
  • glucocorticoid levels can induce protein catabolism which in turn can lead to the degradation of skeletal muscle or the atrophy of intestinal villi.
  • Deficiency in growth hormone results in a variety of medical disorders.
  • the consequences of acquired GH deficiency include profound reduction in lean body mass and concomitant increase in total body fat, particularly in the truncal region. Decreased skeletal and cardiac muscle mass and muscle strength lead to a significant reduction in exercise capacity. Bone density is also reduced.
  • Taiwanese researchers to recommend the discontinuation of use of a dexamethasone regimen to chronic lung disease in children despite its benefits due to its adverse effects on somatic growth at school age (Hendry, J., Postnatal Dexamethasone Treatment Associate with Later Neuromotor and Cognitive Function Impairment and Disability, 2004, N. England J. Med., 350:1304-13).
  • Glucocorticoid therapy is considered essential to the management of asthma; such treatments are often given on a daily basis and for an extended period of time. Recent studies have shown that glucocorticoid administration, while alleviating some symptoms of asthma, may also lead to airway damage or airway remodeling (see Dorscheid, D. R. et al., “ Apoptosis of airway epithelial cells induced by corticosteroids” , Am. J. Respir. Crit. Care Med., 2001, 164:1939-4947).
  • Cushing's syndrome is a condition which is associated with a number of negative catabolic effects, including reduced growth velocity and lean body mass.
  • a person suffering from Cushing's syndrome usually has a large, round face (commonly referred to as a “moon face”) with slender arms and legs in proportion to the thickened trunk.
  • the catabolic effects of this disease results in limited muscle capacity which leads to pronounced physical weakness. The skin becomes thin, bruises easily and heals poorly when bruised or cut.
  • the heightened glucocorticoid levels associated with Cushing's syndrome results in chronic, elevated blood pressure, osteoporosis, diminished resistance to infections, the development of kidney stones and diabetes.
  • Mental disturbances, including depression and hallucinations, have been found to occur in persons having Cushing's syndrome. Women usually experience irregular menstrual cycles. Children with Cushing's syndrome grow slowly and remain short. In some people, the adrenal glands also produce large amounts of androgens. Chronic glucocorticoid excess associated with Cushing's syndrome, left untreated, increases the risk of premature death.
  • Ghrelin likely enhances the activity of growth hormone releasing hormone (GHRH)-secreting neurons while concomitantly acting as a functional somatostatin (SS) antagonist (Ghigo, E. et al., Eur J Endocrinol (1997) 136(5):445-60).
  • SS somatostatin
  • glucocorticoids Long-term administration of glucocorticoids is one of the most used treatments in clinical medicine but is known to suppress GH secretion and action. In fact, glucocorticoids inhibit pulsatile GH release, reduce GH receptor expression and signal transduction and inhibit IGF-1 bioactivity. Recognition of glucocorticoid-mediated antagonism of GH secretion and action has renewed interest in GH therapy or treatments to stimulate GH release as a potential means to reverse some of the most harmful side effects of glucocorticoid long-term treatment, such as growth inhibition and catabolic effects. Different studies suggest that the detrimental effects of glucocorticoid can be variably overcome by GH treatment, but long-term GH therapy also has the potential for adverse effects and requires further surveillance and study.
  • This invention relates to a method and pharmaceutical composition for inhibiting the effect of glucocorticoids on growth hormone secretion, and more particularly to the pharmaceutical administration of [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 which has been found useful as a ghrelin agonist to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.
  • Ghrelin is a naturally-occurring peptide having the following sequence: H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-NH 2 (Kojima M. et al. Nature (1999) 402(6762):656-60). Ghrelin is produced by epithelial cells lining the fundus of the stomach which stimulate appetite and adiposity. Ghrelin levels are increased prior to a meal and decreased thereafter.
  • Ghrelin levels in the plasma of obese individuals are lower than those in leaner individuals and levels of ghrelin increases during the time of the day from midnight to dawn in thinner individuals suggesting a flaw in the circulatory systems of obese individuals (Yildiz, B. et al., Proc. Natl. Acad. Sci. USA (2004) 101:10434-9) thus leading to the belief that ghrelin has the ability to regulate homeostasis.
  • Ghrelin was discovered to powerfully stimulate growth hormone secretion from the anterior pituitary gland and is believed to be an endogenous ligand for the GH secretagogues (GHS) subtype-1a receptor (hereinafter may be referred to as “GHS-1a”; Kojima et al., Nature (1999) 402:656-60) both in animals and in humans (Ukkola, O et al., 2002 Ann. Med . (2002) 34:102-8).
  • GGS-1a GH secretagogues subtype-1a receptor
  • the invention provides a method to ameliorate the catabolic effects of excess glucocorticoids in an individual in need of such treatment comprising administering to the individual a therapeutically effective amount of a ghrelin agonist.
  • the ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • the excess glucocorticoids are the result of a disease or a condition. In another aspect of said first embodiment, the excess glucocorticoids are the result of the long term administration of glucocorticoids to the individual. In a further aspect of the immediately foregoing, the administered glucocorticoid is dexamethasone.
  • the glucocorticoid induced catabolic effects include, but are not limited to, a reduction in growth, a reduction in growth rate, a reduction in body weight, a reduction in lean body mass, a reduction in IGF-1 levels and/or a reduction in bone mass.
  • the individual receiving the method of the invention to ameliorate a reduction in growth, a reduction in growth rate, a reduction in body weight, a reduction in lean body mass, a reduction in IGF-levels and/or a reduction in bone mass is a child or an adult.
  • the ghrelin agonist useful to ameliorate a reduction in growth, a reduction in growth rate, a reduction in body weight, a reduction in lean body mass, a reduction in IGF-1 levels and/or a reduction in bone mass is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • the reduction in growth, growth rate, body weight, lean body mass, IGF-1 levels and/or bone mass is a result of the administration of dexamethasone.
  • the administration includes, but is not limited to, intramuscular, intranasal, intraperitoneal, and intravenous administration.
  • the invention provides a method allowing for the long term administration of therapeutic doses of glucocorticoids to treat a disease or condition, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of glucocorticoids by the administration of a ghrelin agonist.
  • the ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • the glucocorticoid is dexamethasone.
  • a ghrelin agonist such as [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2
  • the invention provides a method allowing for the long term administration of therapeutic doses of glucocorticoids to a child to treat respiratory distress of prematurity, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of glucocorticoids by the administration of a ghrelin agonist.
  • the ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • the glucocorticoid is dexamethasone.
  • the invention provides a method allowing for the long term administration of therapeutic doses of glucocorticoids to treat asthma, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of glucocorticoids by the administration of a ghrelin agonist.
  • the ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • the glucocorticoid is dexamethasone.
  • the invention provides a method allowing for the long term administration of therapeutic doses of glucocorticoids to treat a disease or condition, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of glucocorticoids by the administration of a ghrelin agonist wherein the administration includes, but is not limited to, intramuscular, intranasal, intraperitoneal, and intravenous administration.
  • FIG. 1 Dose-response effects of [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 (indicated as “A”) versus ghrelin on phosphoinositide turnover in transfected CHO-K1 cells expressing hGHS1a receptor. Results are the mean ⁇ SD of three independent experiments.
  • FIG. 2 Dose-response effect of intravenous administration of [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 (indicated as “A”) on GH secretion in freely moving rats. Dose values are expressed as nmole/kg. Each experimental point represents the mean ⁇ SEM of four replicate animals. When no error bars are illustrated, the SEM is smaller than the height occupied by the symbol representing the mean.
  • FIG. 3 The effect of the different pharmacological treatment on somatic growth in young male rats, dexamethasone (also referred to herein as “DEX”) treatment significantly decreased (P ⁇ 0.01) somatic growth whereas [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 (indicated as “A”) administration significantly increased (P ⁇ 0.05) somatic growth as compared to SAL-treated rats.
  • FIG. 4 Panel A: the effect of the different pharmacological treatment on 24-h food intake expressed as a percent of the control value. Data represented the mean ⁇ SEM of nine determinations performed at irregular intervals from day 33 to day 47 after birth.
  • Panel B the effect of the different pharmacological treatments on food efficacy calculated as a ratio between food intake (g) and body weight (g) measured over the same time interval at different stages of growth. Data represents the meant SEM of eight rats. *P ⁇ 0.05; ** ⁇ 0.01 vs SAL-treated rats (Dunnett's test).
  • Panel C the effect of the different pharmacological treatments on the cumulative food intake measured over the indicated time intervals at different stages of growth.
  • the inventors have devised a new method of treating catabolic dysfunctions induced by glucocorticoid excess.
  • the present invention comprises the administration to a human or animal afflicted with, or likely to develop, a catabolic dysfunction, a therapeutically effective amount of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 .
  • glucocorticoid excess or “excess glucocorticoids” refers to patients afflicted with a condition associate with chronic exposure to above-normal levels of glucocorticoids. As a result, these patients can be characterized as having high blood levels of glucocorticoids. Examples include excessive secretion of adrenocortical hormones such as cortisol in Cushing's syndrome, or chronic exposure to glucocorticoids such as dexamethasone used as anti-inflammatory agents in many clinical scenarios such as severe respiratory distress of prematurity.
  • Catabolism refers to a net breakdown of anatomical tissue.
  • a “catabolic effect” is an effect which involves a breakdown of anatomical tissues.
  • Catabolic effects induced by excess glucocorticoids may include, but are not limited to, reduction in growth, reduction in growth rate, reduction in body weight, reduction in lean body mass, reduction in IGF-1 levels and reduction in bone mass.
  • a subject experiences a “reduction in growth” when the subject is shorter than the desired height, which is usually judged in relation to height and weight for similar subjects of similar ages, which is often judged in relation to height and weight charts for children and/or adults.
  • a subject experiences a “reduction in growth rate” when the rate of growth of the subject is slower or less than the rates for similar subjects of similar ages, which is often judged in relation to height and weight charts for children and/or adults.
  • body weight or “body mass” refers to the total weight of a subject, including both fat and lean tissues.
  • body weight or “body mass” refers to the total weight of a subject, including both fat and lean tissues.
  • lean body weight refers to the weight of the lean tissues of a subject and excludes the weight of fat tissues of a subject.
  • a subject experiences “reduced lean body mass” when the lean body mass of the subject is less than that of similar subjects of similar ages.
  • a “reduction of IGF-1” levels refers to a condition in which the circulating levels of IGF-1 in a subject are reduced as compared to similar subjects of similar ages.
  • a reduction in growth, reduction in growth rate, reduction in body weight, reduction in lean body mass, reduction in IGF-1 levels and reduction in bone mass may also be measured and compared to levels or values obtained in the same subject prior to the onset of the disease or condition requiring the administration of glucocorticoids.
  • catabolic dysfunction is a condition which induces a catabolic biochemical pathway in which the degradation of an anatomical structure.
  • prevention of a catabolic state we include an effect in which protein synthesis is stimulated and/or an effect in which the rate of protein degradation is decreased.
  • ameliorate refers to the alleviation, reduction, suppression, diminishing or otherwise lessening of the catabolic effects of excess glucocorticoids.
  • a “protein wasting disease” or a “protein wasting condition” is a disease or condition in which protein, i.e., lean body mass, decreases or declines or diminishes to an undesired degree and/or at an undesired rate.
  • An example of a protein wasting disease is cachexia.
  • long term administration of a medicament such as a glucocorticoid
  • a medicament for treatment of a chronic condition.
  • the medicament may be administered for as long as the condition exits and the patient receive benefit from the administration. Long term administration may last for several weeks, several months or even several years. In some instances, the medicament is administered for the lifetime of the patient
  • spontaneous growth refers to growth of the body in contrast to the viscera.
  • pulsatile growth hormone (or GH) secretion refers to the rhythmical secretion of CH from the anterior pituitary gland to maintain a constant level of GH in the blood stream.
  • respiratory distress of prematurity which may also be referred to as “respiratory distress syndrome” is a breathing disorder of premature newborns in which the air sacs (alveoli) in a newborn's lungs do not remain open because the production of surfactant is absent or insufficient.
  • lypolysis refers to the decomposition or splitting up of fat.
  • the present invention is intended to be used in all catabolic dysfunctions whether enteral or parenteral.
  • enteral is intended to indicate that portion of the alimentary canal between the stomach and the anus.
  • parenteral denotes that region outside of the digestive tract.
  • the administration of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 can be by both enteral and parenteral means.
  • Enteral administration is accomplished is by using small-bore tubing placed via the nose into the gastric or duodenal regions, or through surgical implantation as in, for example, gastrostomy or jejunostomy.
  • Parenteral routes of administration include, but are not limited to, such routes as subcutaneous, intramuscular, or intravenous injection, nasopharyngeal or mucosal absorption or transdermal absorption.
  • ghrelin, or a functional analogue thereof in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2
  • the therapeutically effective amount of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 is in a liquid form which is administered from a reservoir directly via the placement of a needle into a large vein of the patient wherein the needle is connected to the reservoir by tubing.
  • an “agonist” is a molecule which binds to the same receptor or receptors as an exemplary molecule and elicits the same or a similar response from the receptor or receptors of that exemplary molecule.
  • a “ghrelin agonist” is a molecule which binds to the same receptor or receptors as native ghrelin and elicits the same or a similar response from binding to said receptors.
  • the term “functional analogue” is another phrase used to describe an agonist molecule.
  • a “therapeutically effective amount” for the administration of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 are those amounts large enough to prevent the catabolism or atrophy of the tissues of the body in order to maintain metabolic homeostasis.
  • therapeutic composition or “pharmaceutical composition” is defined as comprising of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , which may also contain excipients such as water, minerals and other compatible carriers.
  • compositions may comprise ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , alone or in combination with other chemicals.
  • Ghrelin analogues taught, discussed and disclosed in the following patent publications may be used to practice the claimed methods:
  • Ghrelin analogs may be administered in any suitable dosage form, e.g., formulated with any known organic or inorganic pharmaceutical carrier.
  • Carriers so utilized should be inert (non-reactive).
  • conventional carriers e.g., gelatin, lactose, starches or the like may be incorporated therein.
  • the preparations may be sterilized or may additionally contain known auxiliary substances, such as preserving, stabilizing, wetting or emulsifying agents, salts for regulating osmotic pressure, buffers, extenders and/or other conventional carriers and the like.
  • the content of active substances in these preparations may be within the range of from about 5 to 100 milligrams, preferably from about 5 to 10 milligrams.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • Carriers or occlusive dressings can be used to increase skin permeability and enhance absorption.
  • Containers containing the composition of the invention can be used to facilitate the administration of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , according to the method of the invention.
  • These containers are designed to contain, for example, the daily dosage of ghrelin, or a functional analogue thereof, in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , to be administered to the patient.
  • amino acid has isomeric forms, it is the L form of the amino acid that is represented unless otherwise explicitly indicated.
  • BSA bovine serum albumin
  • Dmab 4- ⁇ N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino ⁇ benzyl
  • HOAT O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
  • HOBt 1-hydroxy-benzotriazole
  • TIS triisopropylsilane
  • TFFH tetramethylfluoroforamidinium hexafluorophosphate
  • N-terminal amino acid is isonipecotic acid (Inp)
  • the abbreviation stands for the structure of:
  • a peptide of this invention is also denoted herein by another format, e.g., (Aib 2 )hGhrelin(1-28)-NH 2 , with the substituted amino acid(s) from the natural sequence placed between the first set of parentheses (e.g., Aib 2 for Sere in hGhrelin).
  • the numbers between the second set of parentheses refer to the number of amino acids present in the peptide (e.g., hGhrelin(1-18) refers to amino acids 1 through 18 of the peptide sequence for human Ghrelin).
  • NH 2 in e.g., (Aib 2 )hGhrelin(1-28)-NH 2 , indicates that the C-terminus of the peptide is amidated.
  • (Aib 2 )hGhrelin(1-28), or, alternatively, (Aib 2 )hGhrelin(1-28)-OH indicates that the C-terminus is the free acid.
  • amino acids with achiral-center are provided in the L-enantiomer.
  • Reference to “a derivative thereof” refers to a modified amino acid such as the corresponding D-amino acid, a N-alkyl-amino acid, a ⁇ -amino acid, or a labeled amino acid.
  • Acyl refers to R′′—C(O)—, where R′′ is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl or substituted alkylaryl.
  • Alkyl refers to a hydrocarbon group containing one or more carbon atoms where multiple carbon atoms if present are joined by single bonds.
  • the alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.
  • Substituted alkyl refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), —OH, —CN, —SH, —NH 2 , —NHCH 3 , —NO 2 , —C 1-20 alkyl substituted with 1 to 6 halogens, —CF 3 , —OCH 3 , —OCF 3 , and —(CH 2 ) 0-20 —COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine, and iodine
  • alkyl acids containing, or consisting of —(CH 2 ) 0-20 —COOH include 2-norbornane acetic acid, tert-butyric acid and 3-cyclopentyl propionic acid.
  • Heteroalkyl refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group is replaced with one or more of the following groups: amino, amido, —O—, —S— or carbonyl. In different embodiments 1 or 2 heteroatoms are present.
  • “Substituted heteroalkyl” refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine and iodine), —OH, —CN, —SH, —NH 2 , —NHCH 3 , —NO 2 , —C 1-20 alkyl substituted with 1 to 6 halogens, —CF 3 , —OCH 3 , —OCF 3 and —(CH 2 ) 0-20 —COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine and iodine
  • Alkenyl refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present.
  • the alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.
  • Substituted alkenyl refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), —OH, —CN, —SH, —NHz, —NHCH 3 , —NO 2 , —C 1-20 alkyl substituted with 1 to 6 halogens, —CF 3 , —OCH 3 , —OCF 3 and —(CH 2 ) 0-20 —COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine, and iodine
  • Aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated ⁇ -electron system containing up to two conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups.
  • the aryl is a 5- or 6-membered ring.
  • Preferred atoms for a heterocyclic aryl are one or more sulfurs, oxygens and/or nitrogens. Examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole and 9-anthracene.
  • Aryl substituents are selected from the group consisting of —C 1-20 alkyl, —C 1-20 alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine); —OH, —CN, —SH, —NH 2 , —NO 2 , —C 1-20 alkyl substituted with 1 to 5 halogens, —CF 3 , —OCF 3 and —(CH 2 ) 0-20 —COOH.
  • the aryl contains 0, 1, 2, 3 or 4 substituents.
  • halo encompasses fluoro, chloro, bromo and iodo.
  • (C 1 -C 12 )hydrocarbon moiety encompasses alkyl, alkenyl and alkynyl and, in the case of alkenyl and alkynyl, there are C 2 -C 12 .
  • Alkylaryl refers to an “alkyl” joined to an “aryl”.
  • biotinyl is
  • Lys(biotinyl) is
  • Lys(myristyl) is
  • Ghrelin analogs can contain D-amino adds, L-amino acids or a combination thereof.
  • amino acids present in a ghrelin analog are the L-enantiomers.
  • Preferred derivatives of analogs of the invention comprise D-amino acids, N-alkyl-amino acids, ⁇ -amino acids and/or one or more labeled amino acids (including a labeled version of a D-amino acid, an N-alkyl-amino acid, or a ⁇ -amino acid).
  • a labeled derivative indicates the alteration of an amino acid or amino acid derivative with a detectable label. Examples of detectable labels include luminescent, enzymatic and radioactive labels. Both the type of label and the position of the label can affect analog activity. Labels should be selected and positioned so as not to substantially alter the activity of the ghrelin analog at the GHS receptor. The effect of a particular label and position on ghrelin activity can be determined using assays measuring ghrelin activity and/or binding.
  • a protecting group covalently joined to the C-terminal carboxyl group reduces the reactivity of the carboxyl terminus under in vivo conditions.
  • the carboxyl terminus protecting group is preferably attached to the ⁇ -carbonyl group of the last amino acid.
  • Preferred carboxyl terminus protecting groups include amide, methylamide, and ethylamide.
  • the ghrelin analogues of the invention can be produced using the techniques discussed herein to produce the preferred embodiment, [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , as well as techniques that are well known in the art.
  • a polypeptide region of a ghrelin analog can be chemically or biochemically synthesized and modified. Techniques for chemical synthesis of polypeptides are also well known in the art (Vincent in Peptide and Protein Drug Delivery , New York, N.Y., Dekker, 1990).
  • the peptides of this invention can be prepared by standard solid phase peptide synthesis (Stewart, J. M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984)).
  • Boc amino acids (Midwest Bio-Tech®, Fishers, Ind.; Novabiochem®, San Diego, Calif.) were used with the following side chain protection: Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly-OH, Boc-Gln-OH, Boc-Lys(2ClZ)-OH, Boc-Ser(Bzl)-OH, Boc-Phe-OH, Boc-Glu(OcHex)-OH and Boc-Pro-OH.
  • Boc-Gly-OH was used as the residue at position 1
  • Fmoc-Aib-OH was used as the residue at position 2
  • Fmoc-Glu(OtBu)-OH was used for the residue at position 3 in the sequence.
  • the synthesis was carried out on a 0.25 mmol scale.
  • the Boc groups were removed by treatment with 100% TFA for 2 ⁇ 1 minute Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 minutes.
  • the protected peptide-resin was transferred into a reaction vessel on a shaker for manual synthesis.
  • the resin was mixed with Fmoc-Glu(OtBu)-OH (2.5 mmol) which was pre-activated with HBTU (2.0 mmol), HOBt (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF. The mixture was shaken for 2 hours. This coupling step was repeated.
  • the resin was treated with a TFA solution containing 5% water and 5% TIS for 2 hours to remove the tBu protecting group in the side chain of the Glu residue.
  • the resin was neutralized with 10% DIEA in DMF and washed with DMF and DCM and then treated with hexylamine (2.0 mmol), DIC (2.0 mmol), HOBT (2.0 mmol) in 5 ml of DCM for 2 ⁇ 2 hours.
  • the resin was washed with DMF and treated with 25% piperidine in DMF for 30 minutes to remove the Fmoc protecting groups. After washing with DMF and DCM, the resin was transferred into the reaction vessel on the ABI 430A® peptide synthesizer for the assembly of the rest two residues.
  • the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2 ⁇ 30 minutes to remove the DNP group on the histidine side chain.
  • the N-terminal Boc group was then removed by treatment with 100% TFA for 2 ⁇ 2 minutes.
  • the peptide-resin was washed with DMF and DCM and dried under reduced pressure.
  • the final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (50 mg) at 0° C. for 75 minutes.
  • HF was removed by a flow of nitrogen. The residue was washed with ether (6 ⁇ 10 mL) and extracted with 4N HOAc (6 ⁇ 10 mL).
  • This crude product was purified on a reverse-phase preparative HPLC using a column (4 ⁇ 43 cm) of C 18 DYNAMAX-100A® (Varian®, Walnut Creek, Calif.). The column was eluted with a linear gradient from 75% A and 25% B to 55% A and 45% B at flow rate of 10 mL/minute for an hour where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. Fractions were collected and checked on an analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 31.8 mg of a white solid were obtained.
  • CHO-K1 cells expressing the human recombinant GHS-1a receptor were harvested and resuspended in a phosphate-buffered saline solution containing 25 mM glucose and 75 mM sucrose (PBS+GS) and pre-incubated with 25 ⁇ Ci/ml myo[ 3 H]inositol for 60 min/37° C. The cells were washed, resuspended in PBS+GS, and incubated with LiCl (100 mM) and GHS peptides in a final volume of 0.30 ml.
  • PBS+GS phosphate-buffered saline solution containing 25 mM glucose and 75 mM sucrose
  • LiCl 100 mM
  • GHS peptides in a final volume of 0.30 ml.
  • Rats (200-250 g) were anesthetized with chlorohydrate (500 mg/kg) and fit with a jugular-right atrial cannula at least 18 hours prior to the experiment.
  • blood samples were withdrawn into heparinized syringes at ⁇ 10 and 0 minutes from fully conscious, freely-moving rats.
  • the rats were injected with either [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 or vehicle (a sterile saline solution with 0.25% (w/v) bovine serum albumin) via the indwelling cannula.
  • Subsequent blood samples were withdrawn approximately 10, 20, 40 and 60 minutes after the initial injection. Plasma was separated and stored until assay for GH (see FIG. 2 ).
  • the animals were provided with water and food ad libitum consisting of an approximate 3200 calories/kg daily diet of standard pellet chow provided by Piccioni, Gessate-Milano, Italy (containing at least 19% protein, 3% fat and 56% carbohydrate).
  • the subgroup of 16 studied animals was further divided into groups of 8 and treated subcutaneously three times daily (at approximately 9:00 am, 1:00 pm and 5:00 pm) with either 80 nmoles/kg of the preferred ghrelin analog [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 (IPSEN, Milford, Mass.) dissolved in a sterile saline solution with 0.25% bovine serum albumin or vehicle (the saline-bovine serum albumin solution alone). This regimen continued for 24 days during which time the studied animals were weighed two times per week.
  • the cumulative food intake for a 24-hour period of time was measured. Beginning on the 46 th day (i.e., the animals were 46 days old), the length of the test and control animals from nose to anus was measured (hereinafter referred to as “the nose-anal length”). On the 47 th day (i.e., the animals were 47 days old), all food was denied to the test subjects commencing at 8:00 am. Small samples of blood were taken via percutaneous puncture of the tail to assess blood glucose levels during the treatment period.
  • test animals received two intravenous administrations of [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 at approximately 9:00 am and 1:00 pm.
  • the studied animals were sacrificed by rapid decapitation at approximately 2:00 pm, trunk blood collected for hormone level determinations, and the epididymal fat pads removed and weighed.
  • Plasma insulin, IGF-1, and corticosterone levels were all measured using commercial RIA kits (Insulin and Corticosterone kits were both obtained from ICN-Biomedicals, Asse-Relegem, BELGIUM and the rIGF-1 test kit was obtained from Mediagnostic GMbH, Tubingen, GERMANY). Glucose concentration was determined using the Glucotrend® Soft Test System blood glucose meter (Roche Diagnostics, Barcelona, SPAIN).
  • results reported in FIGS. 3-6 are expressed as the mean ⁇ SEM of eight replicate test subjects. Data was analyzed for statistical significance by one-way ANOVA which determines the variation (variance) within the groups and how that variation translates into variation (i.e. differences) between the groups, taking into account how many subjects there are in each group. This statistical analysis was followed by Dunnett's t test or Tukey's test for multiple comparisons used to determine whether the means of the control groups differed significantly. The linear correlation analysis was performed either by Pearson's parametric test or by Spearman's nonparametric test. A P value below 0.05 was considered significant.
  • Dexamethasone significantly reduced final body weight and final body length; [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 increased linear growth in saline-treated rats and reversed growth inhibition in dexamethasone-treated rats (see Table 1).
  • the inhibitory effects of dexamethasone on somatic growth was paralleled by decreased 24 hour food intake, diminished food efficiency (defined as a ratio between body weight gain and food intake measured over the same time interval) and lowered plasma IGF-1 levels when compared to vehicle-treated rats.
  • [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 induced an increase in food intake and efficiency and plasma IGF-1 in saline-treated rats, and reversed the inhibitory effects of dexamethasone (see Table 2, FIG. 4 ). These results demonstrated that [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 is a therapeutic option to reverse the catabolic effects induced by glucocorticoids.
  • Dexamethasone administration did not significantly affect cumulative 24-hour food intake up to 10 days from the beginning of the treatment (data not shown). After that time, a significant reduction in the amount of food consumed by dexamethasone-treated test subjects was observed compared to the amount consumed by the saline-treated animals; [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 -treated subjects showed increased daily food intake when compared with saline-treated animals; food consumption for test subjects receiving both dexamethasone and [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 did not differ significantly from saline only-treated animals with respect to feeding behavior ( FIG.
  • [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 -treated subjects showed higher IGF-1 levels compared to saline-treated animals; [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 partially reversed IGF-1 suppression in dexamethasone-treated subjects. Dexamethasone treatment tended to increase plasma insulin concentration, but the effect did not reach statistical significance.
  • [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 administration kept plasma insulin levels unchanged in the saline-treated animals as compared with vehicle; the simultaneous administration of dexamethasone and [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 significantly induced insulin secretion and the increase of plasma insulin was paralleled by a decrease of plasma glucose levels.
  • Ghrelin analogs in particular [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 can be formulated and administered to a subject using the guidance provided herein along with techniques well known in the art.
  • the preferred route of administration ensures that an effective amount of compound reaches the target.
  • Guidelines for pharmaceutical administration in general are provided in, for example, Remington's Pharmaceutical Sciences 18 th Edition, Ed. Gennaro, Mack Publishing, 1990, and Modem Pharmaceutics 2 nd Edition, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990, both of which are hereby incorporated by reference herein.
  • Ghrelin analogs can be prepared as acidic or basic salts.
  • Pharmaceutically acceptable salts in the form of water- or oil-soluble or dispersible products) include conventional non-toxic salts or the quaternary ammonium salts that are formed, e.g., from inorganic or organic acids or bases.
  • salts include acid addition salts such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyan
  • Ghrelin analogs can be administered using different routes including oral, nasal, by injection, transdermal, and transmucosally.
  • Active ingredients to be administered orally as a suspension can be prepared according to techniques well known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents.
  • these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants.
  • Administered by nasal aerosol or inhalation formulations may be prepared, for example, as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, employing fluorocarbons, and/or employing other solubilizing or dispersing agents.
  • Ghrelin analogs may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form.
  • the injectable solution or suspension may be formulated using suitable non-toxic, parenterally-acceptable diluents or solvents, such as Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • Suitable dosing regimens are preferably determined taking into account factors well known in the art including type of subject being dosed; age, weight, sex and medical condition of the subject; the route of administration; the renal and hepatic function of the subject; the desired effect; and the particular compound employed.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the daily dose for a subject is expected to be between 0.01 and 1,000 mg per subject per day.
  • Ghrelin analogs can be provided in a kit.
  • a kit typically contains an active compound in dosage forms for administration.
  • a dosage form contains a sufficient amount of active compound such that a desirable effect can be obtained when administered to a subject during regular intervals, such as 1 to 6 times a day, during the course of 1 or more days.
  • a kit contains instructions indicating the use of the dosage form to achieve a desirable affect and the amount of dosage form to be taken over a specified time period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/224,972 2006-03-10 2007-03-09 Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment Abandoned US20100227806A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/224,972 US20100227806A1 (en) 2006-03-10 2007-03-09 Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78117206P 2006-03-10 2006-03-10
US12/224,972 US20100227806A1 (en) 2006-03-10 2007-03-09 Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
PCT/US2007/006042 WO2007106385A2 (en) 2006-03-10 2007-03-09 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

Publications (1)

Publication Number Publication Date
US20100227806A1 true US20100227806A1 (en) 2010-09-09

Family

ID=38509995

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/224,972 Abandoned US20100227806A1 (en) 2006-03-10 2007-03-09 Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
US12/283,161 Expired - Fee Related US8076281B2 (en) 2006-03-10 2008-09-10 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US13/287,211 Expired - Fee Related US8741835B2 (en) 2006-03-10 2011-11-02 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/283,161 Expired - Fee Related US8076281B2 (en) 2006-03-10 2008-09-10 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US13/287,211 Expired - Fee Related US8741835B2 (en) 2006-03-10 2011-11-02 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment

Country Status (4)

Country Link
US (3) US20100227806A1 (de)
EP (1) EP2012809B1 (de)
ES (1) ES2424970T3 (de)
WO (1) WO2007106385A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US9821042B2 (en) 2012-02-07 2017-11-21 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CN101282738B (zh) * 2005-09-28 2015-09-16 益普生制药股份有限公司 生长素释放肽类似物
RU2566708C2 (ru) * 2005-09-29 2015-10-27 Ипсен Фарма С.А.С. Композиции и способы стимуляции двигательной функции желудочно-кишечного тракта
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
WO2008039415A2 (en) * 2006-09-27 2008-04-03 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the n-terminal
EP2547351B1 (de) * 2010-03-15 2016-04-27 Ipsen Pharma S.A.S. Pharmazeutische zusammensetzungen aus wachstumshormon-sekretagogen-rezeptorliganden
RU2625793C2 (ru) * 2011-12-23 2017-07-19 Ипсен Мэньюфэкчеринг Айэлэнд Лимитед Способ синтеза терапевтических пептидов
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750771A (en) 1904-01-26 Ball-bearing sheave
US748904A (en) 1904-01-05 Adams
US721916A (en) 1902-06-07 1903-03-03 Ideal Cash Register Company Cash-register.
US721557A (en) 1902-07-28 1903-02-24 Chauncey W Gay Paper-box machine.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
PT1197496E (pt) * 1999-07-23 2007-08-29 Kenji Kangawa Novos péptidos
ATE344273T1 (de) * 2000-09-18 2006-11-15 Applied Research Systems Verfahren zur herstellung von 21-hydroxy-6,19- oxidoprogesteron (21oh-6op)
US7666833B2 (en) * 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
BR0306685A (pt) * 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
KR101065471B1 (ko) * 2002-07-23 2011-09-16 입센 파마 에스.에이.에스 그렐린 유사체
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821042B2 (en) 2012-02-07 2017-11-21 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Also Published As

Publication number Publication date
US20090163416A1 (en) 2009-06-25
EP2012809A2 (de) 2009-01-14
EP2012809A4 (de) 2009-11-04
ES2424970T3 (es) 2013-10-10
US20120129767A1 (en) 2012-05-24
US8741835B2 (en) 2014-06-03
US8076281B2 (en) 2011-12-13
WO2007106385A3 (en) 2008-01-24
WO2007106385A2 (en) 2007-09-20
EP2012809B1 (de) 2013-05-22

Similar Documents

Publication Publication Date Title
US8076281B2 (en) Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US20200347110A1 (en) Composition and Methods for Stimulating Gastrointestinal Motility
CA2664558C (en) Analogs of ghrelin substituted at the n-terminal
JP5000848B2 (ja) グレリン含有医薬組成物
TWI331922B (en) Growth hormone releasing peptides
US7485620B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
EP2478011A1 (de) Fluorinierte ghrh-antagonisten
KR20070069207A (ko) 성장 호르몬 분비 촉진물질 및 그의 용도
US7452865B2 (en) Antagonistic analogs of GH RH (2003)
Bouillanne et al. Growth hormone therapy in elderly people: an age‐delaying drug?
WO2013190520A2 (en) Gh-releasing agents in the treatment of vascular stenosis and associated conditions
Nass et al. Therapeutic potentials of GH secretagogues in adults
NASS et al. Growth Hormone Secretagogues Edited by E. Ghigo, M. Boghen, FF Casanueva and C. Dieguez© 1999 Elsevier Science BV All rights reserved

Legal Events

Date Code Title Description
AS Assignment

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TULIPANO, GIOVANNI;GIUSTINA, ANDREA;REEL/FRAME:019853/0801

Effective date: 20070906

AS Assignment

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMEASURE INCORPORATED;REEL/FRAME:020944/0567

Effective date: 20070815

Owner name: BIOMEASURE, INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CULLER, MICHAEL DEWITT;DONG, ZHENG XIN;REEL/FRAME:020944/0374

Effective date: 20070813

STCB Information on status: application discontinuation

Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION)